Mesoblast Limited Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid Arthritis  
1/30/2013 9:33:04 AM

MELBOURNE, Australia, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (FDA) to commence a Phase 2 clinical trial evaluating a single intravenous infusion of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) for the treatment of active rheumatoid arthritis.